Integrative Analysis of Human Glioblastoma Multiforme

NCT ID: NCT03005132

Last Updated: 2016-12-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-01-31

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Integrative analysis of GBM

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators will analyzed proteomes of paired normal brain tissues and GBM, sequenced transcriptomes, perform whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal brain tissue, primary GBM carcinoma, and its synchronous matched metastasis, as well as analyzed genomics of GBM characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

GBM

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

GBM; Integrative Analysis; WES

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normal brain tissue

Normal brain tissue from GBM patients

Normal brain tissue

Intervention Type OTHER

The investigators will extract total protein, DNA and RNA from the samples.

GBM tissues

GBM tissues from GBM patients

Normal brain tissue

Intervention Type OTHER

The investigators will extract total protein, DNA and RNA from the samples.

Metastasis tissues

Metastasis tissues from GBM patients

Normal brain tissue

Intervention Type OTHER

The investigators will extract total protein, DNA and RNA from the samples.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Normal brain tissue

The investigators will extract total protein, DNA and RNA from the samples.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≤ 75 years with histologically proven GBM
* No severe major organ dysfunction
* World Health Organization (WHO) performance status of 0 or 1
* No prior cancer chemotherapy

Exclusion Criteria

* Age ≥ 76
* Severe major organ dysfunction
* WHO performance status of \>1
* Prior cancer chemotherapy
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jilin University

OTHER

Sponsor Role collaborator

Ganzhou City People's Hospital

OTHER

Sponsor Role collaborator

Shanghai 10th People's Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Da Fu

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Da Fu, PhD

Role: PRINCIPAL_INVESTIGATOR

Shanghai 10th People's Hospital

Xiaoming Zhong, MD

Role: STUDY_DIRECTOR

Ganzhou City People's Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Shanghai Tenth People's Hospital

Shanghai, Shanghai Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Da Fu, PhD

Role: CONTACT

Phone: 00-86-21-66301604

Email: [email protected]

Yushui Ma, BS

Role: CONTACT

Phone: 00-86-21-66301604

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Da Fu, PhD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.

Reference Type RESULT
PMID: 25651787 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2016-521-Rainy

Identifier Type: -

Identifier Source: org_study_id